Homatropine


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: Ophthalmic Mydriasis and cycloplegia for refraction As homatropine hydrobromide 2% or 5% solution: Instill 1-2 drops into affected eye(s) immediately before the procedure, repeat after 5-10 minutes if necessary. Uveitis As homatropine hydrobromide 2% or 5% solution: Instill 1-2 drops into affected eye(s) bid or tid, or up to 3-4 hourly as needed.
Contraindications
Primary glaucoma, narrow anterior chamber angle glaucoma.
Special Precautions
Patient with keratoconus, down syndrome, brain damage, exposed to high environmental temperature. Children. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness, blurred vision and sensitivity to light, if affected, do not drive or operate machinery. Remove contact lenses prior to ophthalmic administration and reinsert after 15 minutes.
Adverse Reactions
Significant: Fixed dilated pupil, increased ocular pressure; light sensitivity, hyperthermia. Eye disorders: Transient stinging, burning sensation, irritation, follicular conjunctivitis, exudates, mydriasis, ocular hyperaemia, vascular congestion, blurred vision. Gastrointestinal disorders: Dry mouth. Metabolism and nutrition disorders: Oedema. Psychiatric disorders: Drowsiness, somnolence. Skin and subcutaneous tissue disorders: Eczemetoid dermatitis.
Drug Interactions
Enhanced antimuscarinic effect with amantadine, antihistamines, phenothiazine, antipsychotics, and TCA.
CIMS Class
ATC Classification
S01FA05 - homatropine ; Belongs to the class of anticholinergics used as mydriatics and cycloplegics.
Disclaimer: This information is independently developed by CIMS based on homatropine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in